Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of NNC9204-1513 in Healthy Subjects
NCT03444467Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nnc9204-1513 in hypoglycemia (2 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events. Started Feb 2018; status: completed.
02
Drugs
nnc9204-1513
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT03444467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444467.